Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura(National Cancer Center Hospital East), Tanios Bekaii‐Saab(AstraZeneca (United Kingdom)), Yu Sunakawa(St. Marianna University School of Medicine), Thomas E. Stinchcombe(Duke Medical Center), Bradley J. Monk(Creighton University), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Shunji Takahashi(Japanese Foundation For Cancer Research), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Seung Tae Kim(Samsung Medical Center), Lionel Aurelien Kankeu Fonkoua(Mayo Clinic), Jorge Ramos(Seagen (United States)), Hidetoshi Hayashi(Kindai University Sakai Hospital), Roman Groisberg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sang Joon Shin(Yonsei University), Danny Nguyen(Harbin Medical University), Do‐Youn Oh(Seoul National University), Martin Reck(German Center for Lung Research), Nobumasa Mizuno(Aichi Cancer Center), Alicia Okines(Royal Marsden NHS Foundation Trust), Guy Jérusalem(University of Liège), Kazuki Sudo, Cédric van Marcke(Cliniques Universitaires Saint-Luc), Keun‐Wook Lee(Seoul National University Bundang Hospital), Evan Y. Yu(University of Washington), Erika Hamilton(Sarah Cannon), Sherry Tan(Seagen (United States)), Jean-Luc Canon(Grand Charleroi Hospital)
Cited by 100
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k